Achaogen’s Zemdri (plazomicin) Receives FDA Approval for Complicated Urinary Tract Infection (cUTI)

 Achaogen’s Zemdri (plazomicin) Receives FDA Approval for Complicated Urinary Tract Infection (cUTI)

Achaogen’s Zemdri (plazomicin) Receives FDA Approval for Complicated Urinary Tract Infection (cUTI)

Shots:

  • The approval is based on P-III EPIC (Evaluating Plazomicin in cUTI) study results assessing Zemdri (plazomicin, IV) vs Meropenem in 388 patients with cUTI including pyelonephritis aged ≥18 yrs.
  • P-IIIEPIC study results: composite cure rate (CCR) @5 day (88.0% vs 91.4%); CCR at test-of-cure (TOC) (81.7% vs 70.1%)
  • Zemdri (plazomicin, qd) is an aminoglycoside active against carbapenem-resistant (CRE) & extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae used for targetting bacterias including E.coli, Klebsiella pneumoniae and Enterobacter cloacae 

Click here to read full press release/ article | Ref: Achaogen | Image: Achaogen

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post